Aclaris Therapeutics (ACRS) Operating Expenses (2017 - 2025)
Historic Operating Expenses for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $20.4 million.
- Aclaris Therapeutics' Operating Expenses rose 3800.36% to $20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $169.1 million, marking a year-over-year increase of 13037.76%. This contributed to the annual value of $160.7 million for FY2024, which is 2491.8% up from last year.
- Per Aclaris Therapeutics' latest filing, its Operating Expenses stood at $20.4 million for Q3 2025, which was up 3800.36% from $20.2 million recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Operating Expenses registered a high of $108.9 million during Q4 2024, and its lowest value of $14.8 million during Q3 2024.
- Its 5-year average for Operating Expenses is $29.8 million, with a median of $22.0 million in 2021.
- Examining YoY changes over the last 5 years, Aclaris Therapeutics' Operating Expenses showed a top increase of 40370.54% in 2024 and a maximum decrease of 6373.63% in 2024.
- Aclaris Therapeutics' Operating Expenses (Quarter) stood at $24.4 million in 2021, then surged by 50.99% to $36.8 million in 2022, then tumbled by 41.31% to $21.6 million in 2023, then soared by 403.71% to $108.9 million in 2024, then tumbled by 81.22% to $20.4 million in 2025.
- Its last three reported values are $20.4 million in Q3 2025, $20.2 million for Q2 2025, and $19.5 million during Q1 2025.